Drug Profile
BCH 2687
Alternative Names: LEF 553Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Shire Pharmaceuticals Group
- Developer AstraZeneca
- Class Analgesics; Peptides
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 16 Sep 1997 Discontinued-Preclinical for Pain in Sweden (SC)